Does the cytomegalovirus infection cause kidney transplant rejection in Erbil city patients, Kurdistan region of Iraq?

Sardar  Hussein Rasool; Monika Henryka Miasko; Heshu  Jalal Ahmed; Shukur Wasman Smail; Zhikal Omar Khudhur; Shang Ziyad Abdulqadir; Shatha Saadi Jumaah; Abdulkarim Yasin Karim

doi:10.21271/ZJPAS.34.1.8

Authors

Sardar Hussein Rasool Ministry of Education-KRG, Erbil, Kurdistan region, Iraq
Monika Henryka Miasko Department of Medical Microbiology, College of health Science, Hawler Medical University, Erbil, Kurdistan Region, Iraq
Heshu Jalal Ahmed Department of Medical Analysis, Faculty of Applied Science, Tishk International University, Erbil, Kurdistan Region, Iraq
Shukur Wasman Smail 1.Department of Biology, College of Science, Salahaddin University-Erbil, Erbil, Kurdistan Region, Iraq 2.Department of Biology, College of Science, Cihan University-Erbil, Kurdistan Region, Iraq
Zhikal Omar Khudhur Department of Medical Analysis, Faculty of Applied Science, Tishk International University, Erbil, Kurdistan Region, Iraq
Shang Ziyad Abdulqadir Department of Biology, College of Science, Salahaddin University-Erbil, Erbil, Kurdistan Region, Iraq
Shatha Saadi Jumaah Department of Medical Analysis, Faculty of Applied Science, Tishk International University, Erbil, Kurdistan Region, Iraq
Abdulkarim Yasin Karim 1Department of Biology, College of Science, Salahaddin University-Erbil, Erbil, Kurdistan Region, Iraq ,2Department of Biology, College of Science, Cihan University-Erbil, Kurdistan Region, Iraq

DOI:

https://doi.org/10.21271/ZJPAS.34.1.8

Keywords:

Allograft rejection, Inflammation, Cytomegalovirus, Kidney transplantation, Polymerase chain reaction

Abstract

Cytomegalovirus (CMV), the most significant infectious agent, belongs to the family of Herpesviridae. There is a high risk of severe viral reactivation among patients with kidney transplantation, particularly in the first three months after transplantation (where patients are at the peak for immune suppression), The infection has a high morbidity rate. Hence, this study was designed to assess the association of CMV infection with kidney transplantation and recognize the symptoms that are more related to kidney transplantation (KT) in the Erbil city, Kurdistan region of Iraq. The study enrolled 72 patients who received renal allograft from March 2018 to December 2019, and this population has been characterized as Middle Eastern descent and ethnic miscegenation. Data included age and gender of the recipient, type of donor, symptomatic and asymptomatic CMV patients. Quantitative Polymerase Chain Reaction (qPCR) was used to detect and amplify the extracted virus DNA from blood samples. The CMV was found in 43 patients infected with CMV with graft rejection of about 37.21%. While, it was observed in low rate 13.79% in 20 other patients with graft rejection which had free from CMV. The graft rejection rates were significantly higher among the CMV positive group than controls (P= 0.029). In the light of the results of this study, it has been concluded that the CMV infection in patients after kidney transplantation surgery was deemed an important predisposing factor for acute allograft rejection. The study revealed that the screening of CMV among donor could decrease the possibility of kidney graft rejection among recipients.

REFERENCES

AKPOSSO, K., RONDEAU, E., HAYMANN, J.-P., PERALDI, M.-N., MARLIN, C. & SRAER, J.-D. 1997. Long-term prognosis of renal transplantation after preemptive treatment of cytomegalovirus infection. Transplantation, 63, 974-976.

ANDREWS, P. A., EMERY, V. C. & NEWSTEAD, C. 2011. Summary of the British Transplantation Society guidelines for the prevention and management of CMV disease after solid organ transplantation. Transplantation, 92, 1181-1187.

BRENNAN, D. 2001. Cytomegalovirus in renal transplantation. Journal of the American Society of Nephrology, 12, 848-855.

BROWNE, B. J., YOUNG, J. A., DUNN, T. B. & MATAS, A. J. 2010. The impact of cytomegalovirus infection≥ 1 year after primary renal transplantation. Clinical transplantation, 24, 572-577.

CLARK, D. A., EMERY, V. C. & GRIFFITHS, P. D. 2003. Cytomegalovirus, human herpesvirus-6, and human herpesvirus-7 in hematological patients. Semin Hematol, 40, 154-62.

CORDERO, E., CASASOLA, C., ECARMA, R. & DANGUILAN, R. Cytomegalovirus disease in kidney transplant recipients: incidence, clinical profile, and risk factors. Transplantation proceedings, 2012. Elsevier, 694-700.

DANOVITCH, G. M. 2017. Handbook of kidney transplantation.

DE KEYZER, K., VAN LAECKE, S., PEETERS, P. & VANHOLDER, R. J. A. J. O. K. D. 2011. Human cytomegalovirus and kidney transplantation: a clinician's update. 58, 118-126.

DE MATOS, S. B., MEYER, R. & LIMA, F. W. D. M. 2017. Cytomegalovirus Infection after Renal Transplantation: Occurrence, Clinical Features, and the Cutoff for Antigenemia in a University Hospital in Brazil. Infection & chemotherapy, 49, 255-261.

DICKENMANN, M. J., CATHOMAS, G., STEIGER, J., MIHATSCH, M. J., THIEL, G. & TAMM, M. 2001. Cytomegalovirus infection and graft rejection in renal transplantation. Transplantation, 71, 764-767.

FISHMAN, J. A., COSTA, S. F. & ALEXANDER, B. D. 2019. Infection in Kidney Transplant Recipients. Kidney Transplantation - Principles and Practice, 517-538.

GARDINER, B. J., CHOW, J. K., BRILLEMAN, S. L., PELEG, A. Y. & SNYDMAN, D. R. 2019. The impact of recurrent cytomegalovirus infection on long-term survival in solid organ transplant recipients. Transpl Infect Dis, 21, e13189.

GIAKOUSTIDIS, D., ANTONIADIS, A., FOUZAS, I., SKLAVOS, A., GIAKOUSTIDIS, A., OUZOUNIDIS, N., GAKIS, D., KOUBANAGITI, K., MYSERLIS, G. & TSITLAKIDIS, A. Prevalence and clinical impact of cytomegalovirus infection and disease in renal transplantation: ten years of experience in a single center. Transplantation proceedings, 2012. Elsevier, 2715-2717.

HARTMANN, A., SAGEDAL, S. & HJELMESÆTH, J. 2006. The natural course of cytomegalovirus infection and disease in renal transplant recipients. Transplantation, 82, S15-S17.

HEALD-SARGENT, T. A., FORTE, E., LIU, X., THORP, E. B., ABECASSIS, M. M., ZHANG, Z. J. & HUMMEL, M. A. 2020. New Insights Into the Molecular Mechanisms and Immune Control of Cytomegalovirus Reactivation. Transplantation, 104, e118-e124.

HUGHES, D., HAFFERTY, J., FULTON, L., FRIEND, P., DEVANEY, A., LOKE, J., WELSH, K. I., HANDA, A. & KLENERMAN, P. 2008. Donor and recipient CMV serostatus and antigenemia after renal transplantation: an analysis of 486 patients. Journal of clinical virology, 41, 92-95.

JUNG, G., KIM, S.-J., CHOI, G.-S., MOON, J., KIM, J., SIN, M., KIM, E., KWON, C., JOH, J. & LEE, S.-K. The effect of cytomegalovirus antigenemia titer on the efficacy of preemptive therapy for the prevention of cytomegalovirus disease after kidney transplantation. Transplantation proceedings, 2010. Elsevier, 804-810.

LAUTENSCHLAGER, I., SOOTS, A., KROGERUS, L., INKINEN, K., KLOOVER, J., LOGINOV, R., HOLMA, K., KAUPPINEN, H., BRUGGEMAN, C. & AHONEN, J. 1999. Time-related effects of cytomegalovirus infection on the development of chronic renal allograft rejection in a rat model. Intervirology, 42, 279-284.

PATEL, R. & PAYA, C. V. 1997. Infections in solid-organ transplant recipients. Clinical microbiology reviews, 10, 86-124.

RAMANAN, P. & RAZONABLE, R. R. 2013. Cytomegalovirus infections in solid organ transplantation: a review. Infection chemotherapy, 45, 260.

RAMANAN, P., RAZONABLE, R. R. J. I. & CHEMOTHERAPY 2013. Cytomegalovirus infections in solid organ transplantation: a review. 45, 260.

SAGEDAL, S., NORDAL, K. P., HARTMANN, A., SUND, S., SCOTT, H., DEGRÉ, M., FOSS, A., LEIVESTAD, T., OSNES, K. & FAUCHALD, P. 2002a. The impact of cytomegalovirus infection and disease on rejection episodes in renal allograft recipients. American Journal of Transplantation, 2, 850-856.

SAGEDAL, S., NORDAL, K. P., HARTMANN, A., SUND, S., SCOTT, H., DEGRÉ, M., FOSS, A., LEIVESTAD, T., OSNES, K. & FAUCHALD, P. J. A. J. O. T. 2002b. The impact of cytomegalovirus infection and disease on rejection episodes in renal allograft recipients. 2, 850-856.

SCHRÖEDER, R., MICHELON, T., FAGUNDES, I., BORTOLOTTO, A., LAMMERHIRT, E., OLIVEIRA, J., SANTOS, A., BITTAR, A., KEITEL, E., GARCIA, V., NEUMANN, J. & SAITOVITCH, D. 2005. Antigenemia for cytomegalovirus in renal transplantation: choosing a cutoff for the diagnosis criteria in cytomegalovirus disease. Transplant Proc, 37, 2781-3.

SELVEY, L. A., LIM, W. H., BOAN, P., SWAMINATHAN, R., SLIMINGS, C., HARRISON, A. E. & CHAKERA, A. 2017. Cytomegalovirus viraemia and mortality in renal transplant recipients in the era of antiviral prophylaxis. Lessons from the western Australian experience. BMC infectious diseases, 17, 1-10.

TOUPANCE, O., BOUEDJORO‐CAMUS, M. C., CARQUIN, J., NOVELLA, J. L., LAVAUD, S., WYNCKEL, A., JOLLY, D. & CHANARD, J. 2000. Cytomegalovirus‐related disease and risk of acute rejection in renal transplant recipients: a cohort study with case‐control analyses. Transplant international, 13, 413-419.

VON WILLEBRAND, E., PETTERSSON, E., AHONEN, J. & HÄYRY, P. 1986. CMV infection, class II antigen expression, and human kidney allograft rejection. Transplantation, 42, 364-367.

WEIKERT, B. C. & BLUMBERG, E. A. 2008. Viral infection after renal transplantation: surveillance and management. Clinical Journal of the American Society of Nephrology, 3, S76-S86.